


Angiodynamics Inc. (ANGO)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001275187

Angiodynamics Inc. ANGO; healthcare	
Grade	D A B C D E fourth fifth of 371 graded peers percentile 66.2; sampling error 2.5 points; lower is stronger
Rank	246 of 371
Profitability	A/B percentile 22.4
Solvency	C/D percentile 58.4
Growth and financing	D/E percentile 80.3
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$267.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: dilution, distress
Inputs computable	7 of 14
Graded from	filings received through Sep 29, 2026 10 days before the rescans; latest periodic filing 10-Q received Oct 8, 2026
Last close	\$11.22 2026-10-08; market equity \$471.9M
Price used in grade	None



D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: C from Jul 21, 2025, C/D from May 21, 2026, C from Jul 21, 2026, D from Sep 30, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Jul 14, 2026

AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance. AngioDynamics was founded in Queensbury, N.Y., U.S.,

in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 22.4						
Gross profitability		65.5%	32.2%	14.0	372	2026-05-31
Return on invested capital		not computable	9.3%			latest aligned inputs end 2024-05-31; latest annual assets end 2026-05-31
Accruals ratio		(14.6%)	(6.6%)	30.7	811	2026-05-31
Gross margin stability, five years		1.4 pts	2.8 pts	22.3	243	2026-05-31
Solvency, sleeve percentile 58.4						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(2.65)	(0.31)	48.1	756	2026-05-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2024-05-31; latest annual assets end 2026-05-31
Current ratio		2.19x	2.96x	68.7	839	2026-05-31
Growth and financing, sleeve percentile 80.3						
Revenue growth, three-year compound		(1.9%)	10.0%	75.8	415	2026-05-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(20.5%)	2.1%	84.8	704	2026-05-31
Net share issuance, one year		not computable	2.5%			prior share count is 70 days earlier


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 76,056,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
241	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet
242	Fulgent Genetics, Inc. (FLGT)	65.1	D	short runway
243	Entera Bio Ltd. (ENTX)	65.4	D	degenerate inputs
244	Dentsply Sirona Inc. (XRAY)	65.7	D	
245	InspireMD, Inc. (NSPR)	65.9	D	dilution, short runway, distress
246	Angiodynamics Inc. (ANGO) <	66.2	D	fortress balance sheet
247	AIM ImmunoTech Inc. (AIM)	66.5	D	late filer, degenerate inputs, distress
248	Exagen Inc. (XGN)	66.8	D	dilution, fortress balance sheet
249	PTC Therapeutics, Inc. (PTCT)	67.0	D	
250	Cardiff Oncology, Inc. (CRDF)	67.3	D	short runway, fortress balance sheet
251	Amylyx Pharmaceuticals, Inc. (AMLX)	67.6	D	short runway, degenerate inputs

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	44.4%	8.0%	73
Distance from 52-week high	(30.4%)	(31.4%)	51
EBIT to enterprise value	(9.1%)	(1.5%)	33
Free cash flow yield	0.1%	(1.0%)	55
Book value to price	0.35	0.28	57
Sales to price	0.68	0.31	76
Composite equity issuance, five years	9.0%	20.3%	38
Relative strength against the sector, log excess return	0.16	(0.14)	73

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-05-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$34.0M
Operating cash flow, four quarters	\$3.7M
Months of runway	not finite
Days since last periodic filing	1 (10-Q received Oct 8, 2026)
Median daily dollar volume, 63 sessions	\$6.9M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$174.9M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
2	assets	us-gaap:Assets	\$267.2M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
3	operating income	us-gaap:OperatingIncomeLoss	-\$192.4M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	-\$192.4M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$7.3M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
6	total debt	us-gaap:LongTermDebt	\$0	2024-05-31	2024-07-25	10-K	0001628280-24-032989
7	book equity	us-gaap:StockholdersEquity	\$205.6M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$76.1M	2024-05-31	2025-07-18	10-K	0001275187-25-000014
9	total debt	us-gaap:LongTermDebt	\$49.8M	2023-05-31	2024-07-25	10-K	0001628280-24-032989
10	book equity	us-gaap:StockholdersEquity	\$378.3M	2023-05-31	2026-07-14	10-K	0001628280-26-048138
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$44.6M	2023-05-31	2024-07-25	10-K	0001628280-24-032989
12	net income	us-gaap:NetIncomeLoss	-\$36.7M	2026-05-31	2026-09-29	10-K/A	0001140361-26-037995
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.1M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
14	assets	us-gaap:Assets	\$280.1M	2025-05-31	2026-07-14	10-K	0001628280-26-048138
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$320.2M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
16	gross profit	us-gaap:GrossProfit	\$157.7M	2025-05-31	2026-07-14	10-K	0001628280-26-048138
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$292.5M	2025-05-31	2026-07-14	10-K	0001628280-26-048138
18	gross profit	us-gaap:GrossProfit	\$154.7M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$303.9M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
20	gross profit	us-gaap:GrossProfit	\$174.2M	2023-05-31	2025-07-18	10-K	0001275187-25-000014
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$338.8M	2023-05-31	2025-07-18	10-K	0001275187-25-000014
22	gross profit	us-gaap:GrossProfit	\$165.7M	2022-05-31	2024-07-25	10-K	0001628280-24-032989
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$316.2M	2022-05-31	2024-07-25	10-K	0001628280-24-032989
24	current assets	us-gaap:AssetsCurrent	\$163.4M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
25	current liabilities	us-gaap:LiabilitiesCurrent	\$74.7M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$465.9M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
27	operating income	us-gaap:OperatingIncomeLoss	-\$39.9M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
28	book equity	us-gaap:StockholdersEquity	\$170.8M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
29	liabilities	us-gaap:Liabilities	\$96.3M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
30	depreciation amortization	us-gaap:Depreciation	\$14.7M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
31	interest expense	us-gaap:InterestExpense	-\$1.6M	2024-05-31	2024-07-25	10-K	0001628280-24-032989
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.6M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$10.1M	2025-05-31	2026-07-14	10-K	0001628280-26-048138
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.5M	2025-05-31	2026-07-14	10-K	0001628280-26-048138
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$28.2M	2024-05-31	2026-07-14	10-K	0001628280-26-048138
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.5M	2024-05-31	2026-07-14	10-K	0001628280-26-048138

37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$78,000	2023-05-31	2025-07-18	10-K	0001275187-25-000014
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.8M	2023-05-31	2025-07-18	10-K	0001275187-25-000014
39	depreciation amortization	us-gaap:Depreciation	\$10.5M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$36.3M	2026-05-31	2026-07-14	10-K	0001628280-26-048138
41	income tax	us-gaap:IncomeTaxExpenseBenefit	\$442,000	2026-05-31	2026-07-14	10-K	0001628280-26-048138
42	current assets	us-gaap:AssetsCurrent	\$168.3M	2025-05-31	2026-07-14	10-K	0001628280-26-048138
43	current liabilities	us-gaap:LiabilitiesCurrent	\$76.2M	2025-05-31	2026-07-14	10-K	0001628280-26-048138
44	assets	us-gaap:Assets	\$317.7M	2024-05-31	2025-07-18	10-K	0001275187-25-000014
45	assets	us-gaap:Assets	\$532.6M	2023-05-31	2024-07-25	10-K	0001628280-24-032989
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	42,054,450	2026-09-18	2026-09-29	10-K/A	0001140361-26-037995
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	41,332,389	2026-07-10	2026-07-14	10-K	0001628280-26-048138